Process for the Production of Vaccines in Basic Steps
Article Sidebar
Main Article Content
Abstract
Abstract
Understanding the complexity and cost factors associated with vaccine production is essential for informing decision-making by companies, governments, and policymakers considering investments in vaccine manufacturing for immunization and outbreak response. Top multinational companies are well aware of the complex manufacturing processes, the high technological and R&D barriers to market entry and the costs associated with vaccine production. Policymakers in developing countries, donors and investors, however, may not be aware of the factors that continue to limit the number of new manufacturers and have led to attrition and consolidation among existing manufacturers. Through providing a general and consolidated overview of these requirements, we aim to raise awareness in the global community of the benefits and costs of vaccine manufacturing and the challenges associated with maintaining a constant supply.
Downloads
Article Details
Copyright (c) 2025 Jeyaretnam J.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Pollard AJ, Bijker EM. A guide to vaccinology: from basic principles to new developments. Nat Rev Immunol. 2021;21(2):83–100. Available from: https://doi.org/10.1038/s41577-020-00479-7
Yadav D, Agarwal S, Pancham P, Jindal D, Agarwal V, Dubey PK, et al. Probing the Immune System Dynamics of the COVID-19 Disease for Vaccine Designing and Drug Repurposing Using Bioinformatics Tools. Immuno. 2022;2(2):344–371. Available from: http://dx.doi.org/10.3390/immuno2020022
Janeway CA Jr, Travers P, Walport M, Shlomchik MJ. Immunobiology: The Immune System in Health and Disease. 5th ed. New York: Garland Science; 2001. Available from: https://www.ncbi.nlm.nih.gov/books/NBK10757/
Coronaviridae. Fenner's Veterinary. 2017;435–461. Available from: https://doi.org/10.1016/B978-0-12-800946-8.00024-6
Plotkin SA, Orenstein WA, Offit PA. Vaccines. 6th ed. Philadelphia: Elsevier Saunders; 2013. Available from: https://www.scirp.org/reference/referencespapers?referenceid=1284830
Heinz FX, Stiasny K. Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action. NPJ Vaccines. 2021;6(1):104. Available from: https://doi.org/10.1038/s41541-021-00369-6
Astronomo RD, Burton DR. Carbohydrate vaccines: developing sweet solutions to sticky situations?. Nat Rev Drug Discov. 2010;9(4):308–324. Available from: https://doi.org/10.1038/nrd3012
Ewer K, Sebastian S, Spencer AJ, Gilbert S, Hill AVS, Lambe T. Chimpanzee adenoviral vectors as vaccines for outbreak pathogens. Hum Vaccin Immunother. 2017;13(12):3020–3032. Available from: https://doi.org/10.1080/21645515.2017.1383575
Pfizer. Manufacturing and Distributing the COVID-19 Vaccine. 2023. Available from: https://www.pfizer.com/science/coronavirus/vaccine/manufacturing-and-distribution
Reichmuth AM, Oberli MA, Jaklenec A, Langer R, Blankschtein D. mRNA vaccine delivery using lipid nanoparticles. Ther Deliv. 2016;7(5):319–334. Available from: https://doi.org/10.4155/tde-2016-0006
Yu Y, Esposito D, Kang Z, Lu J, Remaley AT, Giorgi V, et al. mRNA vaccine-induced antibodies more effective than natural immunity in neutralizing SARS-CoV-2 and its high affinity variants. Sci Rep. 2022;12:2628. Available from: https://doi.org/10.1038/s41598-022-06629-2
Rijkers GT, Weterings N, Obregon-Henao A, Lepolder M, Dutt TS, van Overveld FJ, Henao-Tamayo M. Antigen Presentation of mRNA-Based and Virus-Vectored SARS-CoV-2 Vaccines. Vaccines (Basel). 2021;9(8):848. Available from: https://doi.org/10.3390/vaccines9080848